Key Eligibility Criteria

- Advanced solid tumors with $KRAS^{G12C}$ mutations
- Received prior standard therapy including treatment with $KRAS^{G12C}$(OFF) inhibitors
- ECOG PS 0–1
- No active brain metastases

Key Endpoints

- Safety and tolerability
- Pharmacokinetics
- Anti-tumor activity



FIG. 1

RMC-6291-001: Clinical Activity in KRAS G12C NSCLC[2]		
Best overall response, n (%)	**Prior G12Ci (n=10)**	**Naïve to G12Ci (n=7)**
Partial response[3]	5 (50)	3 (43)
Stable disease	5 (50)	4 (57)
Progressive disease	0	0
ORR, n (%)	5 (50)	3 (43)
DCR (CR+PR+SD), n (%)	10 (100)	7 (100)



FIG. 2



FIG. 3

RMC-6291-001: Clinical Activity in KRAS G12C CRC(2)	
Best overall response, n (%)	**n=20†**
Partial response(3)	8 (40)
Stable disease	8 (40)
Progressive disease(4)	4 (20)
ORR, n (%)	8 (40)
DCR (CR+PR+SD), n (%)	16 (80)


200mg D15 Mean (N=4)
100mg D15 Mean (N=4)
50mg D15 (N=2)[a]
Plasma Conc (nM)
Time (Hr)
200mg BID D1 Mean (N=2)
200mg D1 Mean (N=4)
100mg D1 Mean (N=4)
50mg D1 Mean (N=3)[a]
Plasma Conc (nM)
Time (Hr)

FIG. 4